Phase 2 Evidence and Impact Analysis
Article 1 — CHG Index and CKM Syndrome (PMID: 42251380)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | CHG as a unified 3-component index tracking the full CKM continuum (incidence → progression → MACCE) is a meaningful conceptual advance over existing single-disease lipid/glucose markers; causal forest ML subgrouping adds methodological novelty |
| Clinical Relevance | 8 | Three standard lab values already drawn in routine practice; directly applicable to population-level risk stratification across T2DM, CVD, and CKD simultaneously; subgroup targeting (high HbA1c, low inflammation) enables precision prevention |
| Population Reach | 9 | CKM syndrome affects hundreds of millions globally; index uses universal routine labs, applicable across healthcare systems regardless of resource level |
| Implementation Speed | 8 | No new tests or infrastructure required; integrates into existing EHR-based risk calculators; regulatory path is essentially a clinical guideline update, not a device approval |
| Evidence Strength | 8 | Two independent cohorts (UK Biobank n=370,916 + Beijing Anzhen n=8,494); 16.5-year median follow-up in discovery cohort; Fine-Gray competing risks model; ML subgroup analysis adds robustness; abstract-only limits full methodological scrutiny |
Key quantitative result: HR 1.47 per 1-SD CHG increase for incident T2DM; HR 1.29 for CKM Stage 1–3 → 4 progression; causal forest ML identified strongest impact in low-inflammation/high-HbA1c subgroup.
External validation: Yes — Beijing Anzhen cohort is a separate validation sample (n=8,494, shorter follow-up but independent population and outcome).
Main limitation: Abstract-only review; full covariate adjustment structure and CHG index formula derivation cannot be fully assessed. Cross-population generalizability (UK + Chinese cohorts) is a strength, but neither cohort is from Sub-Saharan Africa or South Asia.
Equity implications: Universal routine labs lower barriers globally; however, validation cohorts are predominantly European (UKB) and East Asian (Anzhen), leaving South Asian, Black African, and Latin American populations underrepresented. These groups carry some of the highest CKM burden and need prospective representation.
Evidence Maturity: ✅ Confirmed — Validated (prospective design, independent validation cohort, large n)
Article 2 — G.AI Platform for Rare Disease Genomic Diagnosis (PMID: 42251412)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Modular AI platform integrating phenotype standardization (HPO), variant interpretation, and structured clinical reporting in a single traceable pipeline at this scale is architecturally novel; 99.6% Top-20 accuracy across 39,156 cases raises the bar for the field |
| Clinical Relevance | 8 | Addresses the single biggest bottleneck in rare disease diagnosis: expert analyst time. 5–7× speed improvement + near-equivalent accuracy to manual review directly reduces diagnostic odyssey duration for patients |
| Population Reach | 7 | Rare diseases collectively affect ~300M people globally; WES is still inaccessible in many LMICs; but within genomic medicine programs, this is a high-impact scalability tool. Rated 7 relative to the relevant rare disease genomic diagnosis pipeline population |
| Implementation Speed | 6 | Platform is validated and appears deployment-ready for centers with existing WES infrastructure; however, regulatory approval (FDA, CE-IVD) for clinical decision support AI, data sovereignty concerns (China-developed tool), and EHR integration are real friction points outside China |
| Evidence Strength | 7 | 39,156-case multicenter validation is the largest of its kind; however, all centers are in China (geographic/ethnic homogeneity), and the corresponding author is a founder of Xbiolabs (undisclosed conflict potential). Abstract-only limits full assessment of methodology |
Key quantitative result: Top-1 accuracy 95%, Top-3 98%, Top-20 99.6%; HPO concordance 94%; analysis time 48±12 min vs. 4–6 hours manually.
External validation: Multicenter within China but no independent international validation cohort reported.
Main limitation: Conflict of interest (founder-led company); all centers Chinese (limits generalizability to European, Middle Eastern, and African rare disease variant spectra where population genetics differ); no independent replication outside Xbiolabs ecosystem reported.
Equity implications: If accessible globally, could dramatically reduce the rare disease diagnostic gap in under-resourced settings; but current implementation is China-centric. Tool must be validated against non-Han-Chinese population variant databases (ClinVar representation is skewed toward European ancestry) before global deployment.
Evidence Maturity: ⚠️ Revised to Validated (with caveats) — Strong internal multicenter validation, but conflict of interest and geographic restriction warrant independent replication before full confidence.
Article 3 — Fludarabine Dosage and CAR-T Outcomes in LBCL (EBMT) (PMID: 42251173)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Largest registry study to directly address this dose question; prior data were small and conflicting. The definitive "higher is not better" finding for tisa-cel, and the axi-cel superiority finding at standard dosing, meaningfully update clinical assumptions |
| Clinical Relevance | 9 | Directly actionable: lymphodepletion protocols are actively debated and variable across CAR-T centers. HR 1.29 for inferior OS with dose escalation in tisa-cel is a clear harm signal. Practice-changing for a therapy already in standard clinical use |
| Population Reach | 6 | R/R LBCL is a meaningful but numerically limited population (~20,000–30,000 CAR-T-eligible patients/year globally); impact is concentrated but high-intensity |
| Implementation Speed | 8 | No new drug or device needed; protocol change at CAR-T centers is a clinician decision; EBMT guideline update pathway is established; expected uptake within 1–2 years if findings hold in prospective confirmation |
| Evidence Strength | 7 | n=1,498 EBMT registry (largest such dataset); multi-institutional real-world validity; Fine-Gray competing risks applicable; retrospective design and inability to randomize dosing are inherent limitations; confounding by indication possible (sicker patients may have received escalated dosing) |
Key quantitative result: Fludarabine escalation (82.6–120 mg/m²) vs standard: HR 1.29 for inferior OS in tisa-cel (p=0.036); axi-cel standard dosing superior to both tisa-cel groups on OS and PFS.
External validation: Registry data spans multiple EBMT centers 2019–2023 — effectively a multi-institutional validation within a registry framework.
Main limitation: Retrospective design; dose group assignment was not randomized, so confounding by indication (e.g., physicians escalating dose in patients deemed higher-risk) cannot be excluded. Abstract-only.
Equity implications: CAR-T therapy is concentrated in high-income countries with specialized centers. Findings are most relevant in those settings. Access disparities in CAR-T therapy broadly are a systemic equity concern not addressed by this study.
Evidence Maturity: ✅ Confirmed — Validated (large registry, multi-institutional, clinically actionable effect size)
Article 4 — Proteomic Clocks + DL Retinal Phenotypes for Eye Aging (PMID: 42251179)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | First integration of proteomics-based aging clocks with deep learning retinal phenotyping at this scale across four major eye diseases and multiple ethnicities; streamlined cost-reduced clock is a genuine translational contribution |
| Clinical Relevance | 6 | Retinal proteomic aging is a biomarker rather than a treatment; changes ophthalmologic screening paradigms but does not yet alter management algorithms; clinical pathway from "accelerated proteomic aging detected" to actionable intervention is undefined |
| Population Reach | 8 | Cataract, diabetic retinopathy, AMD, and glaucoma collectively affect hundreds of millions globally; transethnic validation (55,000+ participants) strengthens generalizability |
| Implementation Speed | 5 | Proteomic assays are not yet standard-of-care; cost and infrastructure barriers are significant outside research settings; streamlined clock addresses this partially but regulatory and reimbursement pathways are long |
| Evidence Strength | 7 | >55,000 participants across three well-characterized cohorts; discovery + external validation design; transethnic; abstract-only limits full scrutiny of proteomic clock derivation |
Key quantitative result: Proteomic aging acceleration validated across all four major eye diseases; neuroretinal degeneration and microvascular rarefaction as mechanistic correlates; streamlined clock retains predictive performance (specific AUC/HR values not extractable from abstract).
External validation: Yes — cross-cohort validation across three independent cohorts.
Main limitation: Clinical translation pathway from proteomic aging signal to therapeutic or surveillance action is not defined; proteomics not yet routine in ophthalmology workflows.
Equity implications: Transethnic design (including Southeast Asian and Chinese populations via Guangzhou DECS) is a relative strength; access to proteomic profiling will remain unequal globally.
Evidence Maturity: ✅ Confirmed — Validated (multi-cohort, transethnic) but clinical application remains Exploratory
Article 5 — Sex, Frailty, and 30-Day ICU Mortality in Elderly (PMID: 42250989)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Frailty as ICU mortality driver is established; the novel contribution is the rigorous Bayesian quantification of residual sex effect after full frailty adjustment — moving the debate from "is there a sex effect" to "how large is it precisely" |
| Clinical Relevance | 8 | Reframes geriatric ICU triage: frailty-first over sex-first stratification has immediate implications for admission decisions, treatment intensity, and goals-of-care discussions |
| Population Reach | 8 | Elderly ICU admissions are among the fastest-growing healthcare utilization categories globally; frailty assessment is universally applicable |
| Implementation Speed | 8 | CFS is already deployed in many ICUs; this finding supports prioritizing and formalizing CFS use without requiring new tools or infrastructure |
| Evidence Strength | 7 | n=10,363 pooled from three prospective multinational cohorts (VIP1, VIP2, COVIP); Bayesian dual-estimation methodology adds rigor; COVID cohort (COVIP) may introduce disease-specific confounding; pooled analysis of pre-existing cohorts rather than a primary prospective design |
Key quantitative result: Each 1-point CFS increase: 8% higher adjusted 30-day mortality; residual male sex effect: IRR 1.08 (95% CI 1.01–1.15); Bayesian probability of >10% excess male mortality: 2–13%.
External validation: Three independent cohorts used; findings are internally consistent across VIP1, VIP2, and COVIP.
Main limitation: COVID cohort introduces potential selection bias; pooled analysis relies on harmonization of variables across studies with slightly different inclusion criteria.
Equity implications: Female patients carry higher frailty burden (35.3% vs 25.6% frail) — frailty-first frameworks may inadvertently concentrate risk reclassification toward women; sex-sensitive frailty assessment protocols should be developed to ensure this doesn't translate into less aggressive treatment for frail women.
Evidence Maturity: ✅ Confirmed — Validated
Article 6 — Antihypertensives and Breast Cancer Survival in Black Women (PMID: 42251447)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Subgroup-specific HR 0.53 in ER+ Black women with treated hypertension is a striking signal; Black women are severely underrepresented in drug repurposing research; the ER+/ER− differential is mechanistically intriguing |
| Clinical Relevance | 6 | Hypothesis-generating only — subgroup analysis, observational design, non-significant full-cohort result (HR 0.81); cannot recommend treatment change but should drive prospective investigation in this population |
| Population Reach | 7 | Black women have disproportionately high breast cancer mortality and hypertension prevalence; if confirmed, implications extend to a high-burden, underserved population with existing antihypertensive infrastructure |
| Implementation Speed | 4 | Exploratory evidence maturity; requires prospective validation and mechanistic understanding before implementation; drug-specific effects unknown |
| Evidence Strength | 5 | Prospective cohort design is a strength; subgroup analysis of ER+ subset reduces effective n; residual confounding (treated HTN as proxy for healthcare access) is a major alternative explanation; classification_confidence = medium; abstract-only |
Key quantitative result: ER+ subset: HR 0.53 (95% CI 0.34–0.83) for breast cancer-specific death in treated HTN vs. no HTN; full cohort: HR 0.81 (95% CI 0.60–1.10, non-significant).
External validation: None — single cohort, subgroup finding.
Main limitation: Residual confounding is substantial — treated hypertension may proxy for better healthcare access, adherence, and earlier stage diagnosis rather than a pharmacologic effect. Subgroup sample sizes not reported in abstract.
Equity implications: Directly centers an underserved population (Black women, who bear ~40% higher breast cancer mortality than white women in the US). This is the study's primary equity contribution regardless of whether the drug signal validates.
Evidence Maturity: ✅ Confirmed — Exploratory
Article 7 — BEND4 as AML Prognostic Marker and Target (PMID: 42251161)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | BEND4 is previously uncharacterized in AML; the RT-qPCR threshold (Δct <12.75) with 91%/81% sensitivity/specificity outperforming existing models is a genuinely novel biomarker proposal |
| Clinical Relevance | 4 | Mixed human/animal design caps this; no clinical trial data; functional validation is in vitro/in vivo only; real-world clinical utility requires prospective validation (capped at 5 per rules for non-human components, revised to 4 given early stage) |
| Population Reach | 6 | AML adverse-risk is a specific but high-mortality population with unmet need; affects ~30,000 new cases/year in the US alone; globally significant given poor prognosis |
| Implementation Speed | 3 | Preclinical stage; requires prospective clinical validation, regulatory approval for companion diagnostic use; 5–10 year horizon minimum |
| Evidence Strength | 5 | Transcriptomic discovery in n=1,338 + validation in n=350 is respectable; in vivo mouse model provides mechanistic support; mixed species design caps Evidence Strength per scoring rules |
Key quantitative result: RT-qPCR Δct <12.75 discriminates adverse-risk AML: 91% sensitivity, 81% specificity; outperforms existing mutation/expression panels (specific comparators not detailed in abstract).
External validation: Separate validation cohort (n=350 relapse/refractory); no independent prospective validation.
Main limitation: Mixed human/animal design; RT-qPCR threshold requires prospective clinical validation; the comparison benchmark ("outperforms existing models") needs full-text scrutiny.
Equity implications: AML prognosis tools are broadly equity-neutral in principle; access to RT-qPCR is feasible globally if test is standardized.
Evidence Maturity: ✅ Confirmed — Exploratory
Article 8 — PSMA-3Q PET/CT Radiomics for Prostate Cancer Grading (PMID: 42251454)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | PSMA PET/CT radiomics for preoperative grading is an active field; [18F]PSMA-3Q is a less-studied tracer variant; 45% SUVmax threshold optimization is incrementally novel |
| Clinical Relevance | 6 | AUC 0.917 for ISUP ≥4 prediction is clinically meaningful for surgical planning; however, retrospective single-center design and modest n limit confidence |
| Population Reach | 7 | Prostate cancer is the most common male cancer globally; preoperative precision staging has broad application |
| Implementation Speed | 4 | Requires [18F]PSMA-3Q tracer availability (not universally approved), multicenter validation, and regulatory clearance for clinical use |
| Evidence Strength | 5 | n=243 is modest; test set n=53 is small; retrospective single-center; no external multicenter validation; 9 algorithms tested raises multiple comparisons concern |
Evidence Maturity: ✅ Confirmed — Exploratory
Article 9 — AI Foundation Models for Endometrial Cancer Molecular Subtyping (PMID: 42251145)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Real-world validation of foundation models (UNI, CTransPath) under heterogeneous scanner/stain conditions is an important implementation science contribution; stain normalization impact quantification is novel methodologically |
| Clinical Relevance | 6 | H&E molecular subtyping could replace molecular testing in resource-limited settings; AUROC 0.844 for p53abn is promising but suboptimal for clinical use; small subtype sample sizes (n=16 POLEmut) limit precision |
| Population Reach | 6 | Endometrial cancer is the most common gynecological malignancy in high-income countries; molecular subtyping is increasingly mandated in guidelines |
| Implementation Speed | 5 | Foundation models are near deployment-ready; barriers are regulatory approval, scanner standardization, and pathologist workflow integration |
| Evidence Strength | 6 | Real-world heterogeneous data is methodologically appropriate; n=289 total with very small subtype-specific subgroups; retrospective |
Evidence Maturity: ✅ Confirmed — Exploratory
Article 10 — Aerobic Training and Body Composition in Postmenopausal Women (PMID: 42251396)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Aerobic exercise for body composition in postmenopausal women is well-established; dose-response modeling (RCS) is a methodological addition but does not substantially change clinical knowledge |
| Clinical Relevance | 6 | Quantified effect sizes (-2.17 kg weight, -2.02 cm waist) provide clinically useful benchmarks for counseling; lean mass uncertainty is an important clinical gap |
| Population Reach | 7 | Postmenopausal women with obesity represent a very large global population with high cardiometabolic risk |
| Implementation Speed | 9 | Exercise prescription requires no regulatory pathway; findings directly applicable to clinical counseling today |
| Evidence Strength | 7 | 16 RCTs, n=1,571, PRISMA-compliant, dose-response modeling; moderate certainty by authors' own rating |
Evidence Maturity: ✅ Confirmed — Validated
Article 11 — AIPFI Index and Cardiometabolic Multimorbidity (CHARLS) (PMID: 42251331)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Composite AIPFI (metabolic × frailty) is conceptually novel for CMM prediction; trajectory-based K-means clustering adds longitudinal dimension not seen in prior composite index literature |
| Clinical Relevance | 6 | Strong dose-response association (HR 2.46 Q4 vs Q1) but single Chinese cohort; AIPFI formula (AIP × FI) uses routine data — simple to compute |
| Population Reach | 6 | CHARLS is nationally representative of China (~1.4B); Western generalizability unestablished |
| Implementation Speed | 6 | Index computable from routine data; but needs cross-population validation before guideline integration |
| Evidence Strength | 7 | n=7,995, 9-year follow-up, SHAP explainability, trajectory modeling; established nationally representative cohort |
Evidence Maturity: ✅ Confirmed — Validated (within Chinese population)
Article 12 — Baseline Immune Composition and CAR-T Outcomes in R/R LBCL (PMID: 42251370)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | CD4/CD8 ratio as CAR-T predictor is not new; bispecific CD19/CD22 CAR-T context and GBTM trajectory modeling add novelty |
| Clinical Relevance | 5 | HR 0.41 for PFS with higher CD4/CD8 ratio is hypothesis-generating; n=33 is insufficient for practice guidance |
| Population Reach | 5 | R/R LBCL + bispecific CAR-T is a small but high-need population |
| Implementation Speed | 4 | Requires prospective validation in larger cohorts before immune profiling enters standard pre-CAR-T workup |
| Evidence Strength | 3 | n=33; retrospective; 22/33 received PD-1 inhibitor maintenance (major confounder); hypothesis-generating only |
Evidence Maturity: ✅ Confirmed — Exploratory
Article 13 — TNFRSF/Treg Control and GvHD Therapy (Review) (PMID: 42251338)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Synthesizes TNFR2/DR3 agonism as selective Treg expansion strategy preserving GvL — a useful mechanistic roadmap, though narrative review with no new data |
| Clinical Relevance | 5 | Roadmap for future trial design; no immediate practice change from a review |
| Population Reach | 5 | Allogeneic transplant GvHD is a significant but numerically limited population |
| Implementation Speed | 3 | Underlying therapeutic strategies (TNFR2 agonists) are preclinical; review does not accelerate this independently |
| Evidence Strength | 3 | Narrative review, no primary data, classification_confidence = medium |
Evidence Maturity: ✅ Confirmed — Exploratory
Article 14 — AI in Prehospital ACS Assessment (Scoping Review) (PMID: 42251301)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | AI-ECG for ACS is a maturing field; scoping review confirms state of play but doesn't advance it |
| Clinical Relevance | 6 | Combined n=319,709 and AUC up to 0.99 highlight near-readiness of ECG-AI tools; gap analysis for prospective validation is actionable for research funders |
| Population Reach | 8 | ACS is among the leading causes of death globally; prehospital detection has enormous population leverage |
| Implementation Speed | 5 | ECG-AI devices exist but prehospital integration faces infrastructure, certification, and training barriers |
| Evidence Strength | 5 | Scoping review (not systematic); wide AUC variability (0.81–0.99) indicates heterogeneity; no pooled estimate |
Evidence Maturity: ✅ Confirmed — Exploratory
Article 15 — Frailty Indices and Spinal Metastasis Surgery Outcomes (PMID: 42251449)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Frailty in surgical oncology outcomes is established; incremental contribution comparing specific indices |
| Clinical Relevance | 6 | Directly informs preoperative risk counseling; OR 2.94 for mFI-11 and complications is clinically meaningful |
| Population Reach | 5 | Spinal metastasis surgery is a specialized population |
| Implementation Speed | 7 | Frailty indices are calculable from existing preoperative data; already in use in some centers |
| Evidence Strength | 7 | n=17,446; 12 studies; PRISMA-compliant; NOS quality assessment; fixed-effect model appropriate given homogeneous population |
Evidence Maturity: ✅ Confirmed — Validated
Article 16 — Early-Onset Appendiceal Adenocarcinoma Survival (PMID: 42251206)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Appendiceal adenocarcinoma in young adults is a rare and emerging entity; this is the largest single-institution characterization; 60% late recurrence rate in 5-year survivors is a clinically novel and important finding |
| Clinical Relevance | 5 | Single institution, borderline significance (p=0.06 RFS); generates hypothesis for extended surveillance protocols rather than changing initial management |
| Population Reach | 3 | Very rare cancer; relative to affected population the unmet need is high, but absolute numbers are small |
| Implementation Speed | 4 | Extended surveillance protocols could be implemented now; genomic findings (not detailed in abstract) await full-text review |
| Evidence Strength | 4 | n=181 (EOAA n=49); retrospective single institution; primary endpoint p=0.06 |
Evidence Maturity: ✅ Confirmed — Exploratory
Article 17 — LLPS Biomarkers in HPV+ Cervical Cancer (scRNA-seq + ML) (PMID: 42251432)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | LLPS-cancer biology in cervical cancer is novel mechanistically; RPL5/RPL11 suppression pattern is interesting but ML accuracy (69.7%) is insufficient |
| Clinical Relevance | 3 | No clinical utility at 69.7% accuracy; no external validation; single-author study raises quality concerns |
| Population Reach | 6 | Cervical cancer is the fourth most common cancer in women globally, predominantly in LMICs |
| Implementation Speed | 2 | Discovery-only; no clinical translation pathway defined |
| Evidence Strength | 3 | Single-author, no external validation, discovery-only, classification_confidence = medium |
Evidence Maturity: ✅ Confirmed — Exploratory
Article 18 — TyG-ABSI Index as COPD Predictor (Cross-Population) (PMID: 42251267)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | TyG-ABSI is a novel composite for COPD; cross-population CHARLS + NHANES validation is a relative strength |
| Clinical Relevance | 5 | OR 1.6–4.0 gradient is notable but cross-sectional NHANES component limits causal interpretation; AUC >0.96 is likely optimistic |
| Population Reach | 7 | COPD affects ~380M globally; a simple metabolic screening index has broad reach |
| Implementation Speed | 5 | Requires longitudinal prospective validation before integration into COPD screening workflows |
| Evidence Strength | 5 | Cross-sectional for NHANES; NHANES restricted to pre-diabetic only; AUC inflation risk; two-author study |
Evidence Maturity: ✅ Confirmed — Exploratory
Article 19 — Frailty and Sex Differences in BP Control (Vietnam) (PMID: 42251129)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Sex-specific frailty-BP interaction is clinically interesting but conceptually not groundbreaking; LMIC setting adds geographic novelty |
| Clinical Relevance | 5 | OR 2.01 in frail women is clinically plausible; hospital-based cross-sectional limits inference |
| Population Reach | 6 | Elderly hypertension is universal; LMIC application adds underserved population relevance |
| Implementation Speed | 6 | CFS is simple and deployable; sex-stratified screening is immediately actionable if replicated |
| Evidence Strength | 4 | Cross-sectional; hospital-based (not population representative); n=1,038; causality cannot be established |
Evidence Maturity: ✅ Confirmed — Exploratory
Article 20 — Type 2 Endotypes in Airway Diseases (Review) (PMID: 42250977)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | T2 endotyping in asthma/COPD is established; dupilumab and mepolizumab for T2-COPD are recent but already incorporated into guidelines |
| Clinical Relevance | 6 | Practical clinical summary of 8 approved biologics; T2-COPD endotype identification (20–30% of COPD) has real treatment implications |
| Population Reach | 8 | Asthma + COPD together affect ~500M globally |
| Implementation Speed | 6 | Biologics already approved; the review supports existing clinical implementation rather than enabling new pathways |
| Evidence Strength | 3 | Narrative review without systematic search; classification_confidence = medium; publication date predates window |
Evidence Maturity: ✅ Confirmed — Exploratory